Oportuzumab (Anti-EpCAM / TROP1 / CD326)
Oportuzumab (Anti-EpCAM / TROP1 / CD326) is a humanized monoclonal antibody targeting EpCAM. It exhibits potential in treatment of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. MW :145.4 KD.
Supplier | Selleck Chemicals |
---|---|
Product # | A2992 |
Sku # | A2992-1mg*5 |
Pricing | 1mg*5, $1690.00 |